Genomes and Genes
Affiliation: University of Pennsylvania
- Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependenceRiju Ray
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
Neuropsychopharmacology 35:1374-82. 2010..Additional sequencing and characterization of ChAT may reveal functional variants that contribute to nicotine dependence and smoking cessation...
- A functional prodynorphin promoter polymorphism and opioid dependenceRiju Ray
Department of Pharmacology, University of Pennsylvania, Philadelphia, 19104, USA
Psychiatr Genet 15:295-8. 2005..We examined this polymorphism for association in our sample of 168 opioid-dependent patients and 122 ethnically and geographically matched controls...
- Nicotine dependence: biology, behavior, and treatmentRiju Ray
Transdisciplinary Tobacco Use Research Center, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Annu Rev Med 60:247-60. 2009..Enhanced understanding of these dimensions of nicotine dependence may help to advance progress toward lowering the prevalence rate of tobacco use in the U.S. and lowering the rate of tobacco-related morbidity and mortality...
- Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokersMary Falcone
Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
Nicotine Tob Res 13:498-503. 2011..We tested the potential interacting effects of these two risk factors on CPD...
- μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect reliefMary Falcone
Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
Psychopharmacology (Berl) 222:701-8. 2012..The perception that smoking relieves negative affect contributes to smoking persistence. Endogenous opioid neurotransmission, and the μ-opioid receptor (MOR) in particular, plays a role in affective regulation and is modulated by nicotine...
- Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokersJames Loughead
Brain Behavior Laboratory, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Biol Psychiatry 67:715-21. 2010..In rodents and humans, cognitive deficits can be reversed by treatment with the alpha4beta2 nicotinic receptor partial agonist varenicline. This neuroimaging study examined the neural mechanisms that underlie these effects...
- Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokersRiju Ray
Center for Interdisciplinary Research on Nicotine Addiction, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
Proc Natl Acad Sci U S A 108:9268-73. 2011..Future translational investigations can elucidate the role of MORs in nicotine addiction, which may lead to development of novel therapeutics...
- Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trialRiju Ray
Department of Pharmacology, and Transdisciplinary Tobacco Use Research Center, University of Pennsylvania, Philadelphia, PA, USA
Nicotine Tob Res 9:1237-41. 2007....
- Nicotine abstinence-induced cerebral blood flow changes by genotypeZe Wang
Center for Functional Neuroimaging, Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, United States
Neurosci Lett 438:275-80. 2008..While preliminary, these results suggest a neural mechanism through which these genetic variants may be linked with nicotine dependence, and provide further support for increased biological vulnerability in these subgroups of smokers...
- Identification of pharmacogenetic markers in smoking cessation therapyDaniel F Heitjan
Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Am J Med Genet B Neuropsychiatr Genet 147:712-9. 2008..In a panel of 43 randomly selected control SNPs, none is significant by either the Bayesian or the corrected frequentist test...
- Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatmentD F Heitjan
Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104 6021, USA
Pharmacogenomics J 8:391-9. 2008....
- Brain activity and emotional processing in smokers treated with vareniclineJames Loughead
Brain Behavior Laboratory, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
Addict Biol 18:732-8. 2013..Taken together, these results suggest that observed drug effects on brain activity do not reflect affective changes but rather enhanced early processing of perceptual features of facial stimuli. ..
- Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility studyRebecca L Ashare
University of Pennsylvania Perelman School of Medicine, Department of Psychiatry, Philadelphia, PA 19104, USA
Drug Alcohol Depend 126:263-7. 2012..This pilot feasibility study tested whether an AChEI, donepezil, enhanced cognitive performance among healthy smokers...
- Neuroimaging, genetics and the treatment of nicotine addictionRiju Ray
Trandisciplinary Tobacco Use Research Center, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
Behav Brain Res 193:159-69. 2008..The purpose of this review is to provide an outline of the work in neuroimaging, genetics, and nicotine dependence, and to explore the potential for increased integration of these approaches to improve nicotine dependence treatment...
- Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymesRiju Ray
Abramson Cancer Center and Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
J Neurogenet 23:252-61. 2009..Inhibition of the CYP2A6 enzyme to slow nicotine metabolism is a promising approach to increase nicotine availability and potentially reduce harm from tobacco smoking...
- Pharmacogenetics and smoking cessation with nicotine replacement therapyRiju Ray
Department of Psychiatry, The Transdisciplinary Tobacco Use Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
CNS Drugs 21:525-33. 2007..Larger-scale investigations that incorporate pathway-based or genome-wide analysis, as well as intermediate measures of nicotine dependence (i.e. 'endophenotypes'), may be necessary to capture the complexity of pharmacogenetic effects...
- Translating basic science to improve pharmacotherapy for nicotine dependenceJennifer M Phillips
University of Pennsylvania, Philadelphia, Pennsylvania, USA
Nicotine Tob Res 9:S583-98. 2007....
- Dosimetry of 11C-carfentanil, a micro-opioid receptor imaging agentAndrew B Newberg
Department of Radiology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Nucl Med Commun 30:314-8. 2009..The study was conducted within a regulatory framework that required its pharmacological safety to be assessed simultaneously...
- Analysis of variations in the tryptophan hydroxylase-2 (TPH2) gene in cocaine dependenceJohn P Dahl
Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, USA
Addict Biol 11:76-83. 2006..This work suggests that variations in the TPH2 gene are not a risk factor for the development of cocaine dependence, but these findings require confirmation in larger, independent samples of cocaine-dependent and control subjects...